Article

Houston physicians' group settles federal antitrust charges

A Houston physicians' group has settled federal antitrust charges that stemmed from its use of the messenger model of dealing with health plans, according to a report in the AMA's American Medical News.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
Anna Myers, CNP, answers a question during a Zoom video interview
Related Content
Sandip M. Prasad, MD, MPhil
April 27th 2025

UGN-102 positions itself as an alternative to TURBT for low-grade NMIBC

Benjamin P. Saylor
"I would argue that UGN-102 may very well represent a well-tolerated alternative to TURBT as primary treatment for patients with low-grade disease,” says Sandip M. Prasad, MD, MPhil.
Pearls & Perspectives: Updates in Testosterone Therapy, with Andrew Sun, MD at AUA 2025
April 27th 2025

Pearls & Perspectives: Updates in Testosterone Therapy, with Andrew Sun, MD at AUA 2025

Amy M. Pearlman, MD Andrew Y. Sun, MD
Andrew Sun, MD, joins Pearls & Perspectives to discuss innovative approaches to testosterone therapy for enhanced health outcomes.
Blur image of hospital corridor | Image Credit: © jakkapan - stock.adobe.com
April 27th 2025

Estimated DOR of 2 years is seen with UGN-102 in LG-IR-NMIBC

Benjamin P. Saylor
The investigators reported that the median Kaplan-Meier estimate of DOR was 24.2 months.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Pablo Suarez, MS-4 | Credit: UCSF
April 26th 2025

Drinking water contaminants could increase risk of kidney stones, study finds

Patrick Campbell
New research links higher drinking water contaminants to increased kidney stone risk.
Neal D. Shore, MD, FACS
April 26th 2025

CREST: Significant EFS boost seen with sasanlimab plus BCG in NMIBC

Benjamin P. Saylor
“In the patients with CIS, the probability of a continued complete response at 36 months was 92% vs 67.7%," said Neal D. Shore, MD, FACS.
© 2025 MJH Life Sciences

All rights reserved.